Creteil, France

Michèle Ourevitch

This inventor holds 2 USPTO granted patents. Top assignee: Centre National De La Recherche Scientifique. Active years: 2008-2010.


Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2008-2010

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Michèle Ourevitch: Innovator in Malaria Treatment

Introduction

Michèle Ourevitch is a prominent inventor based in Créteil, France. He has made significant contributions to the field of medicine, particularly in the development of treatments for malaria. With a total of 2 patents to his name, Ourevitch is recognized for his innovative approaches to combating this serious disease.

Latest Patents

Ourevitch's latest patents focus on derivatives of artemisinin and their uses in the treatment of malaria. His work includes a new artemisinin derivative, which is described by the general formula (I). This innovative approach aims to enhance the effectiveness of malaria treatments, providing new hope for patients affected by this illness.

Career Highlights

Ourevitch is affiliated with the Centre National de la Recherche Scientifique, a leading research institution in France. His work there has allowed him to explore various avenues in medical research, particularly in the realm of antimalarial drugs. His dedication to research and innovation has positioned him as a key figure in the fight against malaria.

Collaborations

Throughout his career, Ourevitch has collaborated with notable colleagues, including Fabienne Grellepois and Jean-Pierre Begue. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in research.

Conclusion

In summary, Michèle Ourevitch is a dedicated inventor whose work in developing artemisinin derivatives has the potential to significantly impact malaria treatment. His contributions to medical research continue to inspire advancements in the field.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…